Development and Antiparkinsonian Activity of VU0418506, a Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor 4 Homomers without Activity at mGlu2/4 Heteromers

Colleen M. Niswender, Carrie K. Jones, Xin Lin, Michael Bubser, Analisa Thompson Gray, Anna L. Blobaum, Darren W. Engers, Alice L. Rodriguez, Matthew T. Loch, J. Scott Daniels, Craig W. Lindsley, Corey R Hopkins, Jonathan A. Javitch, P. Jeffrey Conn

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Metabotropic glutamate receptor 4 (mGlu4) is emerging as a potential therapeutic target for numerous central nervous system indications, including Parkinson's disease (PD). As the glutamate binding sites among the eight mGlu receptors are highly conserved, modulation of receptor activity via allosteric sites within the receptor transmembrane domains using positive and negative allosteric modulators (PAMs and NAMs, respectively) has become a common strategy. We and others have used PAMs targeting mGlu4 to show that potentiation of receptor signaling induces antiparkinsonian activity in a variety of PD animal models, including haloperidol-induced catalepsy and 6-hydroxydopamine-induced lesion. Recently, mGlu4 has been reported to form heteromeric complexes with other mGlu receptor subtypes, such as mGlu2, and the resulting heteromer exhibits a distinct pharmacological profile in response to allosteric modulators. For example, some mGlu4 PAMs do not appear to potentiate glutamate activity when mGlu2 and mGlu4 are coexpressed, whereas other compounds potentiate mGlu4 responses regardless of mGlu2 coexpression. We report here the discovery and characterization of VU0418506, a novel mGlu4 PAM with activity in rodent PD models. Using pharmacological approaches and Complemented Donor-Acceptor resonance energy transfer (CODA-RET) technology, we find that VU0418506 does not potentiate agonist-induced activity when mGlu2 and mGlu4 are heterodimerized, suggesting that the antiparkinsonian action of mGlu4 PAMs can be induced by compounds without activity at mGlu2/4 heteromers.

Original languageEnglish (US)
Pages (from-to)1201-1211
Number of pages11
JournalACS Chemical Neuroscience
Volume7
Issue number9
DOIs
StatePublished - Sep 21 2016
Externally publishedYes

Fingerprint

Antiparkinson Agents
Modulators
Pulse amplitude modulation
Parkinson Disease
Glutamic Acid
Rodent Diseases
Pharmacology
Allosteric Site
Catalepsy
metabotropic glutamate receptor 4
Oxidopamine
Energy Transfer
Neurology
Haloperidol
Energy transfer
Animals
Central Nervous System
Animal Models
Binding Sites
Modulation

Keywords

  • Allosteric modulator
  • metabotropic glutamate receptor
  • Parkinson's disease

ASJC Scopus subject areas

  • Physiology
  • Biochemistry
  • Cognitive Neuroscience
  • Cell Biology

Cite this

Development and Antiparkinsonian Activity of VU0418506, a Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor 4 Homomers without Activity at mGlu2/4 Heteromers. / Niswender, Colleen M.; Jones, Carrie K.; Lin, Xin; Bubser, Michael; Thompson Gray, Analisa; Blobaum, Anna L.; Engers, Darren W.; Rodriguez, Alice L.; Loch, Matthew T.; Daniels, J. Scott; Lindsley, Craig W.; Hopkins, Corey R; Javitch, Jonathan A.; Conn, P. Jeffrey.

In: ACS Chemical Neuroscience, Vol. 7, No. 9, 21.09.2016, p. 1201-1211.

Research output: Contribution to journalArticle

Niswender, CM, Jones, CK, Lin, X, Bubser, M, Thompson Gray, A, Blobaum, AL, Engers, DW, Rodriguez, AL, Loch, MT, Daniels, JS, Lindsley, CW, Hopkins, CR, Javitch, JA & Conn, PJ 2016, 'Development and Antiparkinsonian Activity of VU0418506, a Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor 4 Homomers without Activity at mGlu2/4 Heteromers', ACS Chemical Neuroscience, vol. 7, no. 9, pp. 1201-1211. https://doi.org/10.1021/acschemneuro.6b00036
Niswender, Colleen M. ; Jones, Carrie K. ; Lin, Xin ; Bubser, Michael ; Thompson Gray, Analisa ; Blobaum, Anna L. ; Engers, Darren W. ; Rodriguez, Alice L. ; Loch, Matthew T. ; Daniels, J. Scott ; Lindsley, Craig W. ; Hopkins, Corey R ; Javitch, Jonathan A. ; Conn, P. Jeffrey. / Development and Antiparkinsonian Activity of VU0418506, a Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor 4 Homomers without Activity at mGlu2/4 Heteromers. In: ACS Chemical Neuroscience. 2016 ; Vol. 7, No. 9. pp. 1201-1211.
@article{4cdb4593009a4dd9aea2ed00b4f0d59f,
title = "Development and Antiparkinsonian Activity of VU0418506, a Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor 4 Homomers without Activity at mGlu2/4 Heteromers",
abstract = "Metabotropic glutamate receptor 4 (mGlu4) is emerging as a potential therapeutic target for numerous central nervous system indications, including Parkinson's disease (PD). As the glutamate binding sites among the eight mGlu receptors are highly conserved, modulation of receptor activity via allosteric sites within the receptor transmembrane domains using positive and negative allosteric modulators (PAMs and NAMs, respectively) has become a common strategy. We and others have used PAMs targeting mGlu4 to show that potentiation of receptor signaling induces antiparkinsonian activity in a variety of PD animal models, including haloperidol-induced catalepsy and 6-hydroxydopamine-induced lesion. Recently, mGlu4 has been reported to form heteromeric complexes with other mGlu receptor subtypes, such as mGlu2, and the resulting heteromer exhibits a distinct pharmacological profile in response to allosteric modulators. For example, some mGlu4 PAMs do not appear to potentiate glutamate activity when mGlu2 and mGlu4 are coexpressed, whereas other compounds potentiate mGlu4 responses regardless of mGlu2 coexpression. We report here the discovery and characterization of VU0418506, a novel mGlu4 PAM with activity in rodent PD models. Using pharmacological approaches and Complemented Donor-Acceptor resonance energy transfer (CODA-RET) technology, we find that VU0418506 does not potentiate agonist-induced activity when mGlu2 and mGlu4 are heterodimerized, suggesting that the antiparkinsonian action of mGlu4 PAMs can be induced by compounds without activity at mGlu2/4 heteromers.",
keywords = "Allosteric modulator, metabotropic glutamate receptor, Parkinson's disease",
author = "Niswender, {Colleen M.} and Jones, {Carrie K.} and Xin Lin and Michael Bubser and {Thompson Gray}, Analisa and Blobaum, {Anna L.} and Engers, {Darren W.} and Rodriguez, {Alice L.} and Loch, {Matthew T.} and Daniels, {J. Scott} and Lindsley, {Craig W.} and Hopkins, {Corey R} and Javitch, {Jonathan A.} and Conn, {P. Jeffrey}",
year = "2016",
month = "9",
day = "21",
doi = "10.1021/acschemneuro.6b00036",
language = "English (US)",
volume = "7",
pages = "1201--1211",
journal = "ACS Chemical Neuroscience",
issn = "1948-7193",
publisher = "American Chemical Society",
number = "9",

}

TY - JOUR

T1 - Development and Antiparkinsonian Activity of VU0418506, a Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor 4 Homomers without Activity at mGlu2/4 Heteromers

AU - Niswender, Colleen M.

AU - Jones, Carrie K.

AU - Lin, Xin

AU - Bubser, Michael

AU - Thompson Gray, Analisa

AU - Blobaum, Anna L.

AU - Engers, Darren W.

AU - Rodriguez, Alice L.

AU - Loch, Matthew T.

AU - Daniels, J. Scott

AU - Lindsley, Craig W.

AU - Hopkins, Corey R

AU - Javitch, Jonathan A.

AU - Conn, P. Jeffrey

PY - 2016/9/21

Y1 - 2016/9/21

N2 - Metabotropic glutamate receptor 4 (mGlu4) is emerging as a potential therapeutic target for numerous central nervous system indications, including Parkinson's disease (PD). As the glutamate binding sites among the eight mGlu receptors are highly conserved, modulation of receptor activity via allosteric sites within the receptor transmembrane domains using positive and negative allosteric modulators (PAMs and NAMs, respectively) has become a common strategy. We and others have used PAMs targeting mGlu4 to show that potentiation of receptor signaling induces antiparkinsonian activity in a variety of PD animal models, including haloperidol-induced catalepsy and 6-hydroxydopamine-induced lesion. Recently, mGlu4 has been reported to form heteromeric complexes with other mGlu receptor subtypes, such as mGlu2, and the resulting heteromer exhibits a distinct pharmacological profile in response to allosteric modulators. For example, some mGlu4 PAMs do not appear to potentiate glutamate activity when mGlu2 and mGlu4 are coexpressed, whereas other compounds potentiate mGlu4 responses regardless of mGlu2 coexpression. We report here the discovery and characterization of VU0418506, a novel mGlu4 PAM with activity in rodent PD models. Using pharmacological approaches and Complemented Donor-Acceptor resonance energy transfer (CODA-RET) technology, we find that VU0418506 does not potentiate agonist-induced activity when mGlu2 and mGlu4 are heterodimerized, suggesting that the antiparkinsonian action of mGlu4 PAMs can be induced by compounds without activity at mGlu2/4 heteromers.

AB - Metabotropic glutamate receptor 4 (mGlu4) is emerging as a potential therapeutic target for numerous central nervous system indications, including Parkinson's disease (PD). As the glutamate binding sites among the eight mGlu receptors are highly conserved, modulation of receptor activity via allosteric sites within the receptor transmembrane domains using positive and negative allosteric modulators (PAMs and NAMs, respectively) has become a common strategy. We and others have used PAMs targeting mGlu4 to show that potentiation of receptor signaling induces antiparkinsonian activity in a variety of PD animal models, including haloperidol-induced catalepsy and 6-hydroxydopamine-induced lesion. Recently, mGlu4 has been reported to form heteromeric complexes with other mGlu receptor subtypes, such as mGlu2, and the resulting heteromer exhibits a distinct pharmacological profile in response to allosteric modulators. For example, some mGlu4 PAMs do not appear to potentiate glutamate activity when mGlu2 and mGlu4 are coexpressed, whereas other compounds potentiate mGlu4 responses regardless of mGlu2 coexpression. We report here the discovery and characterization of VU0418506, a novel mGlu4 PAM with activity in rodent PD models. Using pharmacological approaches and Complemented Donor-Acceptor resonance energy transfer (CODA-RET) technology, we find that VU0418506 does not potentiate agonist-induced activity when mGlu2 and mGlu4 are heterodimerized, suggesting that the antiparkinsonian action of mGlu4 PAMs can be induced by compounds without activity at mGlu2/4 heteromers.

KW - Allosteric modulator

KW - metabotropic glutamate receptor

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=84988591416&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988591416&partnerID=8YFLogxK

U2 - 10.1021/acschemneuro.6b00036

DO - 10.1021/acschemneuro.6b00036

M3 - Article

VL - 7

SP - 1201

EP - 1211

JO - ACS Chemical Neuroscience

JF - ACS Chemical Neuroscience

SN - 1948-7193

IS - 9

ER -